APA (7th ed.) Citation

H, H., C, W., F, J., P, S., & J, L. (2025). Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer. Drug Design, Development and Therapy, ume 19, 2885-2895.

Chicago Style (17th ed.) Citation

H, Han, Wang C, Jiang F, Sun P, and Liu J. "Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine Versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer." Drug Design, Development and Therapy ume 19 (2025): 2885-2895.

MLA (9th ed.) Citation

H, Han, et al. "Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine Versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer." Drug Design, Development and Therapy, vol. ume 19, 2025, pp. 2885-2895.